It’s a brave new world in clinical trials. Join us for a discussion of emerging trends, including decentralized methodologies, AI and machine learning advancements, and the integration of real-world evidence—as well as how these developments translate to the challenging arena of Schedule I psychedelic research. We will also explore adaptive and biomarker-driven trial designs and focus on diversity and ethical considerations—critical components for ensuring that Schedule I trials are as inclusive and comprehensive as possible.
Whether you're a seasoned researcher or new to the field of psychedelic studies, this webinar will illuminate how these pioneering strategies are applicable to Schedule I clinical research in 2024.
Presenters
Kimberly Chew, Attorney
Karen Luong, Partner
Natasha Sumner, Attorney
Who Should Attend
Professionals in clinical research, pharmaceuticals, neuroscience, psychiatry, trail managers, regulatory affairs, and DEI. Academic medical center employees including researchers, scientists, board members, and legal counsel. These individuals may be involved in Schedule I substance research, therapeutic applications of psychedelics, and the development of psychedelic compounds.
Continuing Education Credit
This program is pending approval for California, Colorado, Illinois, Iowa, Kansas, Minnesota, Missouri, Nebraska, Tennessee, Texas, and Wisconsin continuing legal education credit.